Keskin, MuharremTopkac, Ali2024-02-232024-02-2320222148-5607https://doi.org/10.5152/tjg.2022.21875https://hdl.handle.net/20.500.12452/16779Background: There is still no sensitive and specific biomarker that can be used in the diagnosis and follow-up of Crohn's disease, so we aimed to assess the diagnostic accuracy of serum periostin levels in Crohn's disease. Methods: The study included 40 Crohn's disease patients aged 18-70 years and considered in remission (Crohn's Disease Activity Index < 150) at admission. Forty healthy volunteers were included in the study as the control group. Crohn's patients were divided into 3 main groups as <4 years, 4-8 years, and >8 years according to the follow-up period (in the group <4 years, it was subdivided into <2 and 2-4 years). Serum periostin levels were studied by enzyme-linked immunosorbent assay. Results: Forty Crohn's disease patients and 40 control participants were included in the study. In the Crohn's disease group, serum periostin level was 36.55 ng/mL, while it was 21 ng/ml. in the control group, P < .001. Periostin levels in the Crohn's disease group were higher in the groups with disease duration <4 years, 4-8 years, and >8 years compared to the control group (P < .001, P < .001, P = .038, respectively). For the diagnosis of Crohn's disease independent of disease duration, the cut-off periostin level was determined as 27.8 ng/mL, while the sensitivity and specificity for this value were 72.5% and 77.5%, respectively. Conclusion: Serum periostin levels of the patients followed up with the diagnosis of Crohn's disease in remission were found to be significantly higher than the healthy individuals, and cut-off values of serum periostin were obtained to both diagnose Crohn's disease and predict the course of the disease.eninfo:eu-repo/semantics/openAccessPeriostinCrohn's DiseaseSerum BiomarkersCrohn's Disease DiagnosisInflammatory Bowel DiseaseArticle332127135352387812-s2.0-85125683136Q3WOS:000765079600019Q410.5152/tjg.2022.21875